Concepedia

Vladimir Skljarevski

VS

Statistics

Publications

36

Citations

3.7K

H-Index

30

Active since

2003

Affiliations

Eli Lilly (United States)(Current)

Royal Hallamshire Hospital

Technical University of Munich

Inserm

Indiana University – Purdue University Indianapolis

Vladimir Skljarevski is an author at Eli Lilly (United States) specializing in pharmacotherapy, pain medicine, and pharmacology.

Publications per year

2003–2021

36

Publications

36

Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial

Vladimir Skljarevski, Manjit Matharu, Brian A. Millen et al. · Cephalalgia · 2018 · 557 citations · Full text

, , +15

Duloxetine and pregabalin: High-dose monotherapy or their combination? The “COMBO-DN study” – a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain

Solomon Tesfaye, Stefan Wilhelm, Alberto Lledó et al. · Pain · 2013 · 304 citations

, , +17

Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: A 13-week, randomized, placebo-controlled trial

Amy S. Chappell, Melissa J. Ossanna, Hong Liu‐Seifert et al. · Pain · 2009 · 300 citations

, , +17

Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations

Robert H. Dworkin, Dennis C. Turk, Sarah Peirce‐Sandner et al. · Pain · 2012 · 290 citations

, , +16

A Double‐blind, Randomized, Placebo‐controlled Study of the Efficacy and Safety of Duloxetine for the Treatment of Chronic Pain Due to Osteoarthritis of the Knee

Amy S. Chappell, D. Desaiah, Hong Liu‐Seifert et al. · Pain Practice · 2010 · 222 citations · Full text

, , +17

1–5 of 36